EGFR and non-small cell lung carcinoma: For example, Chen et al. found that combination strategy could improve CNS progression-free survival for EGFR-mutated NSCLC [30]; other scholars reported that patients who received RT before crizotinib experienced longer PFS than those without [31]; results from the ALEX study also suggested that patients with prior RT demonstrated numerically higher CNS response rate and numerically lower risk in intracranial progression [9].